LPL and hereditary disease: Likewise and for safety issues, represented in thrombocytopenia and bleeding risks, volanesorsen (Waylivra®; Akcea Therapeutics, Cambridge, MA, USA) has been denied FDA approval for the treatment of familial chylomicronemia syndrome (FCS), a rare genetic disorder caused mainly by mutations in lpl gene or encoding genes required for LPL function [151].